/
ANIP
$84.12-$0.39 (-0.46%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.9B
23M shares
52-week range
$62.61 – $99.50
58% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.25%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$49.06
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $201.6M | $206.5M | $208.5M | $216.1M | $316.4M | $486.8M | $614.4M | $883.4M |
| Cost of revenue | $73.0M | $63.2M | $87.2M | $100.6M | $138.8M | $181.5M | $250.2M | $432.7M |
| Gross profit | $128.6M | $143.4M | $121.3M | $115.5M | $177.6M | $305.3M | $364.2M | $450.6M |
| Gross margin | 63.8% | 69.4% | 58.2% | 53.5% | 56.1% | 62.7% | 59.3% | 51.0% |
| R&D | $15.4M | $19.8M | $16.0M | $11.4M | $22.3M | $34.3M | $44.6M | $51.7M |
| Operating income | $35.4M | $16.4M | −$16.0M | −$39.8M | −$35.3M | $47.0M | $584.0K | $81.2M |
| EBITDA | $69.1M | $60.7M | $28.1M | $3.1M | $25.0M | $106.6M | $63.1M | $207.3M |
| Net income | $15.5M | $6.1M | −$22.5M | −$42.6M | −$47.9M | $18.8M | −$18.5M | $78.3M |
| Net margin | 7.7% | 3.0% | -10.8% | -19.7% | -15.1% | 3.9% | -3.0% | 8.9% |
| EPS (diluted) | 1.32 | 0.50 | -1.88 | -3.40 | -3.05 | 0.94 | -1.04 | 3.32 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.1B | $9.41 | $9.23–$9.56 | 3 |
| 2027 | $1.3B | $10.86 | $10.26–$11.76 | 3 |
| 2028 | $1.3B | $12.41 | $11.94–$13.12 | 1 |
| 2029 | $1.4B | $13.65 | $13.13–$14.43 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1079.61
Price
$84.11
Implied upside
+1183%
Peer comparison
ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
www.anipharmaceuticals.com- Employees
- 970
- IPO / List date
- Sep 13, 1999
- HQ
- PRINCETON, NJ
Held by traders on TradeandTell
No one on the platform currently holds ANIP.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 186,102 | $14.3M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2012-06-04 | 1-for-6reverse |
Recent trades on TradeandTell
No one on the platform has traded ANIP yet.
